| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/15/2023 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 242.5k | $1.34 | $325k | | 03/15/2023 |
| 07/07/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 161.7k | $1.41 | $228k | | 07/07/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 323.4k | $3.06 | $989.6k | | 02/04/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 80.8k | $3.06 | $247.4k | | 02/04/2022 |
| 12/01/2020 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 450k | $16.18 | $7.3M | | 12/01/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 41k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 122.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 13.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 13.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 50.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 21.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 1.5k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 1.5k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 41k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 122.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 13.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 13.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 50.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 21.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 1.5k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 1.5k | $0.00 | $0 | See footnote | 10/20/2020 |